Position in ROIV
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$4,998,554
-$605,599 QoQ
Shares Held
141,242
-30.2% QoQ
Ownership
0.020%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#140
of 494 holders
Holding Since
Dec 2023
10 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ROIV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Mariner, LLC holds $490,050,155 across 152 Biotechnology names. ROIV ranks #12 (1.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JAZZ |
Jazz Pharmaceuticals plc
|
608,615 | $146,657,956 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
134,614 | $66,866,811 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
100,086 | $62,407,624 | |
| 4 | RPRX |
Royalty Pharma plc
|
693,495 | $38,884,263 | |
| 5 | EXEL |
Exelixis, Inc.
|
313,083 | $17,034,845 | |
| 6 | INCY |
Incyte Corp
|
121,988 | $13,828,559 | |
| 7 | BMRN |
Biomarin Pharmaceutical Inc
|
192,607 | $11,020,972 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
28,021 | $8,435,161 |
All Filings in ROIV
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,998,554 | 141,242 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $5,604,153 | 202,316 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $2,024,740 | 93,306 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $1,095,139 | 72,382 | Shares | Sole | 2025-11-14 | |
| 2025-03-31 | $359,415 | 35,621 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $1,253,648 | 105,972 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $988,666 | 85,673 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $265,021 | 25,073 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $267,789 | 25,407 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $182,453 | 16,247 | Shares | Sole | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||